SavWatt USA, Inc. (OTC:SAVW)
SavWatt USA, Inc. -- pioneers in LED lighting -- announced this week the partnership with Pro-EcoSolutions www.pro-ecosolutions.com.
John Romano, President of Pro-EcoSolutions, commented, "Our association with SavWatt and their products will give our firm an advantage in the Energy saving environment. We are looking forward in this relationship and being able to provide our clients with quality LED products."
In other company news, SavWatt USA, Inc. is pleased to announce that it has become an approved member of Energy Star. Having the Energy Star label will enhance the SAVW brand to the public. Energy Star is a government backed program that helps businesses and individuals protect the environment through superior energy efficiency. SAVW has also been registered with the DOE (Department of Energy) and its Lighting Facts Label. This latest accomplishment along with the launch of its factory for LED tubes in January 2011 has made SavWatt USA, Inc. THE leader and brand in LED lighting.
To learn more about SAVW visit: http://www.savwatt.com
Blue Dolphin Energy Company (Nasdaq:BDCO) an independent oil and gas company with operations in the Gulf of Mexico, reported financial results for the three and nine month periods ended September 30, 2010. For the three months ended September 30, 2010 (the "current quarter"), Blue Dolphin announced a net loss of $69,082 on revenues of $740,309 compared to a net loss of $321,386 on revenues of $484,518 for the three months ended September 30, 2009 (the "previous quarter"). The decrease in net loss in the current period was primarily the result of increased revenues from Blue Dolphin's 7% working interest in the Technical Assistance Contract for the Langsa Area, offshore Indonesia, as well as decreased general and administrative and pipeline operating expenses.
Idenix Pharmaceuticals Inc. (Nasdaq:IDIX) a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, announced that the Company will receive a payment of $20 million from the ViiV Healthcare Company for the achievement of a clinical milestone relating to GSK2248761 (known as '761). ViiV Healthcare is developing '761, a drug candidate for the treatment of HIV/AIDS.
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection.
American Video Teleconferencing Corp. (OTCPK:AVOT)
American Video Teleconferencing Corp. is pleased to announce that it has hired a French speaking geologist to search the archives of the Quebec Department of Mines for Rare Earths showings not on a current computer file. AVOT believes the rare earths industry is where it wants to maintain a very strong focus and is looking to expand its holdings. As neither the Federal nor Quebec Governments have carried out any air borne surveys in this area, AVOT will seek a contractor to do an air borne Mag-EM radiometric survey. This survey will cover its present holdings and the immediate surrounding area looking for future acquisitions. We are pleased to be working in the Province of Quebec as it is rated the number one jurisdiction in the world to carry out mineral exploration. The Quebec Government gives a rebate up to 45% for property expenditures.
Telik Inc. (Nasdaq:TELK) announced on December 6,2010 positive results from a Phase 2 multicenter trial of oral ezatiostat hydrochloride in patients with an International Prognostic System Score (IPSS) of low to intermediate-1 risk myelodysplastic syndrome (NYSE:MDS). The presentation entitled Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog, Glutathione-S-transferase P1-1 (GSTP1-1) Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS), Raza, A., Galili, N., Smith, S., Godwin, J., Boccia, R., Myint, H., Mhadevan, D., Mulford, D., Rarick, M., Allison, M A., Melnyk, O., Meng, L., Jones, M., Brown, G., Young, S., List, A., Komrokji, R., Sekeres, M., was given at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL.
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidates in clinical development are Telintra, a modified glutathione analog for the treatment of MDS and Severe Chronic Neutropenia (SCN), and Telcyta® a cancer activated prodrug for the treatment of advanced non-small cell lung cancer and ovarian cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for SavWatt USA, Inc. (OTC:SAVW). Crown Equity Holdings Inc. (OTCPK:CRWE) anticipates to receive 2,000,000 shares of (144) restricted common stock of American Video Teleconferencing Corp. (OTCPK:AVOT) from the company for 12 months IR Services.